Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients

• Published in: European journal of surgical oncology 2022-02, Vol.48 (2), p.356-361
• Main Authors: Sędłak, Katarzyna, Rawicz-Pruszyński, Karol, Mlak, Radosław, Gęca, Katarzyna, Skórzewska, Magdalena, Pelc, Zuzanna, Małecka-Massalska, Teresa, Polkowski, Wojciech P.
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Capecitabine - administration & dosage; Chemotherapy, Adjuvant; Docetaxel - administration & dosage; Epirubicin - administration & dosage; Female; Fluorouracil - administration & dosage; Gastrectomy; Gastric cancer; Guideline Adherence - statistics & numerical data; Humans; Leucovorin - administration & dosage; Male; Middle Aged; Neoadjuvant Therapy; Outcome and Process Assessment, Health Care; Oxaliplatin - administration & dosage; Perioperative Care - standards; Perioperative chemotherapy; Postoperative Complications - epidemiology; Practice Guidelines as Topic; Stomach Neoplasms - pathology; Stomach Neoplasms - therapy; Survival Rate; Textbook outcome
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2021.08.005

Perioperative chemotherapy (POC) in advanced gastric cancer (GC) patients significantly increases the curative resection rate and overall survival (OS). Textbook outcome (TO) represents a composite of surgical quality metrics strongly associated with improved OS. However, the current definition of TO after resection for GC does not include POC. Herein we propose to supplement the current description of TO with an additional feature, POC compliance. The present study aimed to evaluate prognostic impact of thus defined textbook oncological outcome (TOO) among patients undergoing gastrectomy for advanced GC. We collected data from a prospectively maintained database of all patients operated for GC between 2010 and 2020 in our institution. Patients with histologically confirmed and resectable advanced GC but without distant metastases, in whom multimodal treatment was planned by institutional MDT were included. A total of 194 patients were analyzed. In the multivariate analysis, patients with TOO had a 50 % lower risk of death than patients without TOO (medians: NR vs 42 months; HR = 0.50, p = 0.0109). Patients treated with POC had a 43 % lower risk of death than patients treated with only preoperative chemotherapy (medians: 78 vs 33 months; HR = 0.57, p = 0.0450). Patients with a pathological response (PR) in the primary tumor had a 59 % lower risk of death than patients without PR (medians: NR vs 36 months; HR = 0.41, p = 0.0229). POC combined with TO surgery significantly decreased the risk of death in advanced GC patients (medians: NR vs 42 months; HR = 0.35, p = 0.0258). Since TOO is associated with improved survival, it may serve as a multimodal treatment quality parameter in patients with advanced GC.